TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil; Granulocyte colony-stimulating factors
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms TPExtreme
- 19 Feb 2019 Planned End Date changed from 1 May 2021 to 1 Sep 2020.
- 13 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 May 2021.
- 13 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2021.